Shelter Pharma is currently trading at Rs. 41.70, up by 0.90 points or 2.21% from its previous closing of Rs. 40.80 on the BSE.
The scrip opened at Rs. 41.70 and has touched a high and low of Rs. 41.75 and Rs. 41.70 respectively. So far 3000 shares were traded on the counter.
The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 55.80 on 07-Feb-2025 and a 52 week low of Rs. 30.21 on 12-Jan-2026.
Last one week high and low of the scrip stood at Rs. 43.60 and Rs. 37.50 respectively. The current market cap of the company is Rs. 66.64 crore.
The promoters holding in the company stood at 52.32%, while Non-Institutions held 47.68% stake in the company.
Shelter Pharma has expanded its Nutraceutical portfolio with the launch of FitKick Pro powder in three different flavors tapping into rapidly growing domestic and international market. The product is Power - Packed and carefully crafted with potent ingredients to deliver maximum performance benefits without post-workout energy crash. The FitKick Pro Powder provides several health benefits like explosive strength, improved endurance, enhanced focus and muscle pump.
This launch is part of the company’s strategy to expand its Nutraceutical portfolio and strengthen its presence in the wellness and preventive healthcare segment. The launch of this product will contribute positively to the company’s growth prospects and reinforce the company’s commitment to providing high-quality, science-backed nutritional solutions.
Shelter Pharma is engaged in the business of manufacturing herbal products with well-built presence in Human Pharma as well as Veterinary.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1842.80 |
| Dr. Reddys Lab | 1309.95 |
| Cipla | 1374.15 |
| Zydus Lifesciences | 941.40 |
| Lupin | 2469.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: